XMAB24306
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for XMAB24306, covering 2025-02-17 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]